GlassScriptPhysician profile
Karen E Wilks
NPI 1528027208
$3,660.07
in general payments reported to CMS, 2019-2025
28 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $288 · 2021: $675 · 2022: $506 · 2023: $481 · 2024: $657 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.08 | 2019-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Organon LLC | $654.16 | 2021-2025 | Nexplanon, Nuvaring |
| Astellas Pharma US INC | $338.90 | 2021-2025 | Veozah, Myrbetriq |
| Agile Therapeutics, INC. | $263.79 | 2021-2024 | Twirla |
| Hologic Sales and Service, LLC | $177.64 | 2020-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $174.35 | 2019-2025 | |
| Pfizer INC. | $172.09 | 2019-2023 | |
| Amgen INC. | $140.71 | 2019-2024 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $127.74 | 2019-2023 | Gardasil 9 |
| Mayne Pharma Commercial LLC | $108.57 | 2022-2025 | |
| Exeltis, USA INC. | $106.47 | 2019-2025 | Slynd |
| Minerva Surgical, INC | $102.75 | 2023-2025 | |
| Avion Pharmaceuticals | $98.04 | 2019-2021 | |
| Roche Diagnostics Corporation | $83.44 | 2019 | |
| Allergan, INC. | $60.95 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $60.32 | 2019-2025 | Paragard T 380a |
| Sage Therapeutics, LLC | $50.20 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.02 | 2021 | |
| Therapeuticsmd, INC. | $42.76 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $39.48 | 2024 | Myfembree |
| Millicent US INC | $27.67 | 2020-2023 | Intrarosa, Femring |
| Evofem Biosciences, INC. | $26.09 | 2021 | |
| Spr Therapeutics, INC | $22.90 | 2023 | Sprint Pns System |
| Mylan Pharmaceuticals INC. | $16.45 | 2021 | |
| Covidien LP | $15.71 | 2020 | |
| Alydia Health | $15.65 | 2021 | |
| Lupin INC. | $14.07 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Wilks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.